Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular ...
Publications
2 shownRandomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,629
- Institution
- Merck & Co., Inc., Rahway, NJ, USA (United States)
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.